SU2C recognized by CHOP and SITC for support of cancer research

SU2C, Johnson & Johnson collaborate on research project focused on rare disease linked to blood cancers

Stand Up To Cancer and Johnson & Johnson announced a collaboration aimed at supporting research testing a combination of two types of targeted therapies, teclistamab and daratumumab, to treat a rare disease called AL amyloidosis.

November 15, 2024

Vol.50 No.43

In Brief

SU2C announces grants supporting research in six cancer types

Stand Up To Cancer announced grants to several teams of leading cancer investigators in support of cutting-edge research in a variety of cancers including head and neck, pediatric, pancreatic, breast, rectal, and gastro-esophageal cancers, as well as research focused on how the microbiome communicates with the immune system.

October 18, 2024

Vol.50 No.39

In the Archives

Jeffrey Weber on his career, mentors: “Never ever ever ever blow your cool.”

In 2023, Jeffrey S. Weber was named a Fellow of the Academy of Immuno-Oncology, an honor established by the Society for Immunotherapy of Cancer.

October 04, 2024

Vol.50 No.37

Funding Opportunities

SITC accepting nominations for annual awards and the Academy of Immuno-Oncology

The Society for Immunotherapy of Cancer is taking nominations for the SITC Annual Awards and the Academy of Immuno-Oncology.

April 05, 2024

Vol.50 No.14

In Brief

William Nelson named chair of the SU2C scientific advisory committee

Nobel laureate Phillip A. Sharp, who has chaired the Stand Up To Cancer scientific advisory committee since SU2C launched in 2008 is transitioning to emeritus status at the organization.

February 09, 2024

Vol.50 No.06